|
|
 |
|
Viewing report
|
|
|
|
Know the Other "Omics": Exploring Drug and Diagnostics Development Through Proteomics
Decision Resources, Inc., March 2009, Pages: 25
Genomics has paved the way for its cousin, proteomics, to secure its share of the “omics” hype. Researchers look to proteomics to deliver on the promise to assess the viability of drug targets for monitoring disease progression, optimizing disease management, and diagnosing diseases with more precision. While many challenges are inherent, given the complexities of protein-centric science, technological improvements in the field have resulted in important gains for biopharma.
Get the Answers You Need to Shape Your Strategy
- Partnering in proteomics is slowing despite the potential of the associated technologies to revolutionize drug discovery, diagnostics development, and disease management. What problems are inherent in protein biomarker research? What solutions have been developed to help overcome the obstacles?
- Navigating the proteomics research process of preparation, separation, identification, and validation is complex.
- Which step is most critical upstream to improve results downstream?
- Proteomics technologies give rise to a select set of protein biomarkers. What are the differences between biomarkers for drug discovery and those for diagnostics development?
Scope
- Proteomics technologies: 2DGE, MS, MALDI, SELDI, TOF, bioinformatics.
- Proteomics research process: Innovative methods of sample preparation, separation and capture, identifi cation and analysis, and clinical validation.
- Companies with valuable insight into protein biomarker discovery: 20/20GeneSystems, Caprion Proteomics, NextGen BioSciences, Oxford GlycoSciences.
- Outlook: Proteomics is approaching the long-awaited recognition that it has the potential to deserve. Novel tools now in use will improve greatly owing to collaborative initiatives that will stimulate innovation in protein research processes.
|
|
|
|
